Review: New perspectives in the treatment of idiopathic pulmonary fibrosis

Therapeutic Advances in Respiratory Disease

Volumn 2, Issue 2, 2008, Pages 75-93

  Rogliani, Paola ^a   Mura, Marco ^a   Assunta Porretta, Maria ^a   Saltini, Cesare ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

idiopathic interstitial pneumonia; idiopathic pulmonary brosis; treatment

Indexed keywords

ACETYLCYSTEINE; ANTICOAGULANT AGENT; AZATHIOPRINE; BROMHEXINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; ETANERCEPT; GAMMA INTERFERON; GAMMA1B INTERFERON; GC 1008; GLUTATHIONE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; OCTREOTIDE; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WARFARIN;

BONE MARROW TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; FIBROSING ALVEOLITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LOW DRUG DOSE; LUNG ALVEOLUS EPITHELIUM; LUNG FUNCTION; MACROPHAGE; MONOTHERAPY; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; ANTIOXIDANTS; ANTIVIRAL AGENTS; EPITHELIUM; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERFERON-GAMMA; PHOSPHODIESTERASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57149109880     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465808089363     Document Type: Review

References (138)

1. Abdollahi, A., Li, M., Ping, G., Plathow, C., Domhan, S., Kiessling, F. et al. (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary “brosis. J Exp Med 201: 925-935.
2. Abe, R., Donnelly, S.C., Peng, T., Bucala, R., Metz, C.N. (2001) Peripheral blood “brocytes: differentiation pathway and migration to wound sites. J Immunol 166: 7556-7562.
3. ATS (American Thoracic Society) (2000) Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment International Consensus Statement. Am J Respir Crit Care Med 161: 646-664
4. ATS/ERS (American Thoracic Society/European Respiratory Society) (2002) International Multidisciplinary Consensus Classi”cation of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165: 277-304.
5. Antoniou, K.M., Nicholson, A.G., Dimadi, M. Malagari, K. Latsi1, P. Rapti, A. et al. (2006) Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic Pulmonary “brosis. Eur Respir J 28: 496-504.
6. Antoniades, H.N., Bravo, M.A., Avila, R.E., Galanopoulus, T. Neville, J. Selman, M. et al. (1993) Platelet-derived growth factor in idiopathic pulmonary “brosis. J Clin Invest 1990; 86: 1055-64; Nash, J.R., McLaughlin, P.J., Butcher, D., Corrin, B. Expression of tumour necrosis factor- in cryptogenic “brosing alveolitis. Histopathology 22: 343-347.
7. Aono,Y., Nishioka,Y., Inayama, M., Ugai, M., Kishi, J., Uehara, H. et al. (2005) Imatinib as a novel anti”brotic agent in bleomycin-induced pulmonary “brosis in mice. Am J Respir Crit Care Med 171: 1279-1285.
8. Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K. et al. (2005) Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 171: 1040-1047.
9. Beeh, K.M.J., Beier, I.C., Haas, O., Kornmann, P. and Micke, R. Buhl (2002) Glutathione de”ciency of the lower respiratory tract in patients with idiopathic pulmonary “brosis. Eur Respir J 19: 1119-1123.
10. Behr, F.A., Maier, K., Degenkolb, B., Krombach, F. and Vogelmeier, C. (1997) Antioxidative and clinical effects of high-dose N-acetylcysteine in “brosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 156: 1897-1901.
11. Bitterman, P.B., Adelberg, S. and Crystal, R.G. (1983) Mechanisms of pulmonary “brosis: spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders. J Clin Invest 72: 1801-1813.
12. Borok, Z., Buhl, R., Grimes, G.J., Bosker, A.D., Holroyd, K.J., Roum, J.H. et al. (1991) Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary “brosis. Lancet 338: 215-216.
13. Brown, C.H. and Turner-Warwick, M. (1971) The treatment of cryptogenic “brosing alveolitis with immunosuppressant drugs. The Quarterly Journal of Medicine 40: 289-302.
14. Bucala, R., Spiegel, L.A., Chesney, J., Hogan, M. and Cerami, A. (1994) Circulating “brocytes de”ne a new leukocyte subpopulation that mediates tissue repair. Mol Med 1: 71-81.
15. Cantin, A.M., North, S.L., Fells, G.A., Hubbard, R.C. and Crystal, R.G. (1987) Oxidant mediated epithelial cell injury in idiopathic pulmonary “brosis. J Clin Invest 79: 1665-1673.
16. Cantin, A.M., Hubbard, R.C. and Crystal, R.G. (1989) Glutathione de”ciency in the epithelial lining “uid of the lower respiratory tract in idiopathic pulmonary “brosis. Am Rev Respir Dis 139: 370-372.
17. Chambers, R.C. (2003) Role of coagulation cascade proteases in lung repair and “brosis. Eur Respir J 22: Suppl. 44, 33s-35s.
18. Chaudhary, N.I., Roth, G.J., Hilberg, F., Muller-Quernheim, J., Prasse, A., Zissel, G. et al. (2007) Inhibition of PDGF, VEGF and FGF signalling attenuates “brosis. Eur Respir J 29: 976-985.
19. Chilosi, M., Poletti, V., Murer, B., Lestani, M., Cancellieri, A., Montagna, L. et al. (2002) Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary “brosis: the role of N-p63. Lab Invest 82: 1335-1345.
20. Chilosi, M., Poletti, V., Zamò, A., Lestani, M., Montagna, L., Piccoli, P. et al. (2003) Aberrant Wnt/ß-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis. American Journal of Pathology 162: 1495-1502.
21. Chilosi, M., Zamò, A., Dogliosi, C., Reghellin, D., Lestani, M., Montagna, L. et al. (2006) Migratory marker expression in “broblast foci of idiopathic pulmonary “brosis. Respir Res 7: 95.
22. Collard, H.R., Moore, B.B., Flaherty, K.R., Brown, K.K., Kaner, R.J., King Jr,T.E. et al. (2007a). with the Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 176: 636-643.
23. Collard, H.R., Anstrom, K.J., Schwarz, M.I. and Zisman, D.A. (2007b) Sildena”l Improves Walk Distance in Idiopathic Pulmonary Fibrosis. Chest 131: 641-643.
24. Collard, H.R., Ryu, J.H., Douglas, W.W., Schwarz, M.I., Curran-Everett, D., King Jr, T.E. et al. (2004) Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary “brosis. Chest 125: 2169-2174.
25. Colombat, M., Mal, H., Groussard, O., Capron, F., Thabut, G., Jebrak, G. et al. (2007) Pulmonary vascular lesions in end-stage idiopathic pulmonary “brosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Human Pathology 38: 60-65.
26. Crystal, R.G., Fulmer, J.D., Roberts, W.C., Moss, M.L., Line, B.R., Reynolds, H.Y. et al. (1976) Idiopathic pulmonary “brosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 85: 769-788.
27. Crystal, R.G., Bitterman, P.B., Rennard, S.I., Hance, A.J. and Keogh, B.A. (1984) Interstitial lung diseases of unknown cause: disorders characterized by chronic in”ammation of the lower respiratory tract. N Engl J Med 310: 154-66.
28. Daniels, C.E., Wilkes, M.C., Edens, M., Kottom, T.J., Murphy, S.J., Limper, A.H. et al. (2004) Imatinib mesylate inhibits the pro”brogenic activity of TGF-beta and prevents bleomycin-mediated lung “brosis. J Clin Invest 114: 1308-1316.
29. Danill, Z.D., Girlchrist, F.C., Nicholson, A.G., Hansell, D.M., Harris, J., Colby, T.V. et al. (1999) A Histologic Pattern of Nonspeci”c Interstitial Pneumonia Is Associated with a Better Prognosis Than Usual Interstitial Pneumonia in Patients with Cryptogenic Fibrosing Alveolitis. AM J Respir Crit Care Med 160: 899-905.
30. Davies, H.R., Richeldi, L. and Walters, E.H. (2003) Immunomodulatory agents for idiopathic pulmonary “brosis. The Cochrane Database of Systematic Reviews 3: CD003134.
31. Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H.M. et al. (2005) For the IFIGENIA Study Group*High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. N Engl J Med 353: 2229-2242.
32. Denton, C.P., Zheng, B., Evans, L.A., Shi-wen, X., Ong, V.H., Fisher, I. et al. (2003) Fibroblast-speci”c expression of a kinase-de”cient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with “brosis in transgenic mice. J Biol Chem 278: 25109-25119.
33. Dhillon, S., Lyseng-Williamson, K.A. and Scott, L.J. (2007) Etanercept: a review of its use in the management of rheumatoid arthritis. Drugs 67: 1211-1241.
34. Dobashi, N., Fujita, J., Murota, M., Ohtsuki, Y., Yamadori, I., Yoshinouchi, T. et al. (2000) Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary “brosis. Lung 178: 171-179.
35. Douglas, W.W., Ryu, J.H., Swensen, S.J., Offord, K.P., Schoeder, D.R., Caron, G.M., et al. (1998) Colchicine versus prednisone in the treatment of idiopathic pulmonary “brosis. A randomized prospective study. American Journal of Respiratory and Critical Care Medicine 158: 220-225.
36. Douglas, W.W., Ryu, J.H. and Scroeder, D.R. (2000) Idiopathic pulmonary “brosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. American Journal of Respirator y and Critical Care Medicine 161: 1172-178.
37. Dunkern, T.R., Feurstein, D., Rossi, G.A., Sabatini, F. and Hatzelmann, A. (2007) Inhibition of TGF-β induced lung “broblast to myo”broblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572: 12-22.
38. Du Bois, R.M. (1999) Interferon gamma-1b for the treatment of idiopathic pulmonary “brosis. New England Journal of Medicine 341: 1302-1304.
39. Eitzman, D.T., McCoy, R.D., Zheng, X., Fay, W.P., Shen, T., Ginsburg, D. et al. (1996) Bleomycininduced pulmonary “brosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232-237.
40. Elias, J.A., Freundlich, B., Kern, J.A. and Rosenbloom, J. (1990) Cytokine networks in the regulation of in”ammation and “brosis in the lung. Chest 97: 1439-1445.
41. Feghali-Bostwick, C.A., Tsai, C.G., Valentine, V.G., Kantrow, S., Stoner, M.W., Pilewski, J.M. et al. (2007) Cellular and humoral autoreactivity in idiopathic pulmonary “brosis. J Immunol 179: 2592-2599.
42. Flaherty, K.R., Travis, W.D., Colby, T.V., Toews, G.B., Kazerooni, E.A., Groos, B.H. et al. (2001) Histopathologic Variability in Usual and Nonspeci”c Interstitial Pneumonias. Am J Respir Crit Care Med 164: 1722-1727.
43. Fleischmann, R. and Iqbal, I. (2007) Risk: bene”t pro”le of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 24: 239-254.
44. Fukuda,Y., Ishizaki, M., Masuda,Y., Kimura, G., Kawanami, O. and Masugi,Y. (1987) The role of intra-alveolar “brosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 126: 171-182.
45. Galiè, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D. et al. (2005) Sildena”l Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildena”l citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148-2157.
46. Gauldie, J. (2002) In”ammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary “brosis. Am J Respir Crit Care Med 165: 1205-1208.
47. Grigolo, B., Mazzetti, I., Borzi, R.M., Hickson, I.D., Fabbri, M., Fasano, L. et al. (1998) Mapping of topoisomerase II alpha epitopes recognized by autoantibodies in idiopathic pulmonary “brosis. Clin Exp Immunol 114: 339-346.
48. Gross, T.J. and Hunninghake. G.W. (2001) Idiopathic pulmonary “brosis. N Engl J Med 345: 517-525.
49. Gulsvik, A., Kjelsberg, F., Bergmann, A., Froland, S., Rootwelt, K., Vale, I.R. et al. (1986) High-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic “brosing alveolitis: a pilot study. Respiration 50: 252-257.
50. Gunther, A., Enke, B., Markart P., Hammerl, P., Morr, H., Behr, J. et al. (2007) Safety and tolerability of bosentan in idiopathic pulmonary “brosis: an open label study. Eur Respir J 29: 713-719.
51. Gunther, A., Lubke, N., Ermert, M., Schermuly, R.T., Weissmann, N., Breithecker, A. et al. (2003) Prevention of bleomycin-induced lung “brosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 168: 1358-1365.
52. Gurujeyalakshmi, G. and Giri, S.N. (1995) Molecular mechanisms of anti”brotic effect of interferon gamma in bleomycin-mouse model of lung “brosis: downregulation of TGF-b and procollagen I and III gene expression. Exp Lung Res 21: 791-808.
53. Hayashi, T., Stetler-Stevenson, W.G., Fleming, M.V., Fishback, N., Koss, M.N., Liotta, L.A. et al. (1996) Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary “brosis. Am J Pathol 149: 1241-1256.
54. Hemnes, A.R., Zaiman, A. and Champion, H.C. (2007) PDE5A inhibition attenuates bleomycininduced pulmonary “brosis and pulmonary hypertension through inhibition of ROS Generation and RhoA/Rho kinase Activation. Am J Physiol Lung Cell Mol Physiol 2007 Oct 26; [Epub ahead of print]
55. Honoré, I., Nunes, H., Groussard, O., Kambouchner, M., Chambelin, A., Aubier, M. et al. (2003) Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary “brosis. Am J Respir Crit Care Med 167: 953-957.
56. Howell, D.C., Laurent, G.J. and Chambers, R.C. (2002) Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary “brosis. Biochem Soc Trans 30: 211-216.
57. Hunninghake, G.W., Gadek, J.E., Lawley, T.J. and Crystal, R.G. (1981) Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary “brosis. J Clin Invest 68: 259-269.
58. Idell, S., James, K.K., Levin, E.G., Schwartz, B.S., Manchanda, N., Maunder, R.J. et al. (1989) Local abnormalities in coagulation and “brinolytic pathways predispose to alveolar “brin deposition in the adult respiratory distress syndrome. J Clin Invest 84: 695-705.
59. Imokawa, S., Sato, A., Hayakawa, H., Kotani, M., Urano, T. and Takada, A. (1997) Tissue factor expression and “brin deposition in the lungs of patients with idiopathic pulmonary “brosis and systemic sclerosis. Am J Respir Crit Care Med 156: 631-636.
60. Inase, N., Sawada, M., Ohtani,Y., Miyake, S., Isogai, S., Sakashita, H. et al. (2003) Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary “brosis with corticosteroid. Intern Med 42: 565-570.
61. Iyer, S.N., Gurujeyalakshmi, G. and Giri, S.N. (1999) Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung “brosis. J Pharmacol Exp Ther 289: 211-218.
62. Iwano, M., Plieth, D., Danoff, T.M., Xue, C., Okada, H., Neilson, E.G. et al. (2002) Evidence that “broblasts derive from epithelium during tissue “brosis. J Clin Invest 110: 341-350.
63. Johnson, M.A., Wan, S.K., Snell, N.J.C., Nunn, A.J., Darbyshire, J.H., Turner Warwick, M. et al. (1989) Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic “brosing alveolitis. Thorax 44: 280-288.
64. Kakugawa, T., Mukae, H., Hayashi, T., Ishii, H., Abe, K., Fujii, T. et al. (2004) Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary “brosis. Eur Respir J 24: 57-65.
65. Katzenstein, A.L. and Myers, J.L. (1998) Idiopathic pulmonary “brosis: clinical relevance of pathologic classi”cation. Am J Respir Crit Care Med 157: 1301-1315.
66. Khalil, N., O'Connor, R.N., Unruh, H.W., Warren, P.W., Flanders, K.C., Kemp, A. et al. (1991) Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary “brosis. Am J Respir Cell Mol Biol 5: 155-162.
67. Kinder, B.W., Collard, H.R. and King Jr, T.E. (2006) Anticoagulant therapy and idiopathic pulmonary “brosis. Chest 130: 302-303.
68. King, T.E. Jr, Schwarz, M.I., Brown, K., Tooze, J.A., Colby, T.V., Waldron Jr, J.A. et al. (2001) Idiopathic pulmonary “brosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164: 1025-1032.
69. King, T.E. Jr, Behr, J., Brown, K.K., du Bois, R.M., Lancaster, L., de Andrade, J.A. et al. (2007) A Randomized Placebo-Controlled Trial of Bosentan in Patients with idiopathic pulmonary “brosis. Am J Resp Crit Care 177: 75-81.
70. Kinnula,V.L., Hodgson, U.A., Lakari, E.K., Tan, R.J., Sormunen, R.T., Soini, Y.M. et al. (2006) Extracellular superoxide dismutase has a highly speci”c localization in idiopathic pulmonary “brosis/usual interstitial pneumonia Histopathology 49: 66-74.
71. Kolb, M., Kirschner, J., Riedel, W., Wirtz, H. and Schmidt, M. (1998) Cyclophosphamide pulse therapy in idiopathic pulmonary “brosis. Eur Respir J 12: 1409-1414.
72. Kondoh, Y., Taniguchi, H., Yokoi, T., Nishiyama, O., Ohishi, T., Kato, T. et al. (2005) Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary “brosis and “brosing nonspeci”c interstitial pneumonia. Eur Respir J 25: 528-533.
73. Kotani, I., Sato, A., Hayakawa, H., Urano, T., Takada,Y., Takada, A. et al. (1995) Increased procoagulant and anti”brinolytic activities in the lungs with idiopathic pulmonary “brosis. Thromb Res 77: 493-504.
74. Kubo, H., Nakayama, K., Yanai, M., Suzuki, T., Yamaya, M., Watanabe, M. et al. (2005) Anticoagulant therapy for idiopathic pulmonary “brosis. Chest 128: 1475-1482.
75. Kuwano, K., Nakashima, N., Inoshima, I., Hagimoto, N., Fujita, M., Yoshimi, M. et al. (2003) Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J 21: 232-240.
76. Kwekkeboom, D.J., Krenning, E.P., Kho, G.S., Breeman, W.A. and Van Hagen, P.M. (1998) Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 25: 1284-1292.
77. Lebtahi, R., Moreau, S., Marchand-Adam, S., Debray, M.P., Brauner, M., Soler, P., Marchal, J. et al. (2006) Increased Uptake of 111In-Octreotide in Idiopathic Pulmonary Fibrosis. J Nucl Med 47: 1281-1287.
78. Lettieri, C.J., Nathan, S.D., Barnett, S.D., Ahmad, S. and Shorr, A.F. (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary “brosis. Chest 129: 746-752.
79. Liu, J.-Y., Sime, P.J., Wu, T., Sakuntala Warshamana, G., Pociask, D., Tsai, S.-Y. et al. (2001) Transforming Growth Factor-β1 Overexpression in Tumor Necrosis Factor-α Receptor Knockout Mice Induces Fibroproliferative Lung Disease. Am J Respir Cell Mol Biol 25: 3-7.
80. Lundblad, L.K.A., Thompson-Figueroa, J., Leclair, T., Sullivan, M.J., Poynter, M.E., Irvin, C.G. et al. (2005) Tumor Necrosis Factor-alpha overexpression in lung disease. A single cause behind a complex phenotype. Am J Respir Crit Care Med 171: 1363-1370.
81. Lynch, J.P. and McCune,W.J. (1997) Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 155: 395-420.
82. Mackenzie, D.J. (1951) Effect of cortisone on diffuse pulmonary “brosis; interim report. Treat Serv Bull 6: 475-477.
83. Maher, T.M., Wells, A.U. and Laurent, G.J. (2007) Idiopathic pulmonary “brosis: multiple causes and multiple mechanisms? Eur Respir J 30: 835-839.
84. Martinet, Y., Rom, W.N., Grotendorst, G.R., Martin, G.R. and Crystal, R.G. (1987) Exaggerated spontaneous release of platelet derived growth factor by alveolar macrophages from patients with idiopathic pulmonary “brosis. New Engl J Med 317: 202-209.
85. Meuret, G., Fueter, R. and Gloor, F. (1978) Early stage of fulminant idiopathic pulmonary “brosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone. Respiration 36: 228-233.
86. Meyer, A., Buhl, R. and Magnussen, H. (1994) The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary “brosis. Eur Respir J 7: 431-436.
87. Moolman, J.A., Bardin, P.G., Rossouw, D.J. and Joubert, J.R. (1991) Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 46: 592-595.
88. Myers, J.L. and Katzenstein, A.L. (1988) Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest 94: 1309-1311.
89. Nagai, S., Hamada, K., Shigematsu, M., Taniyama, M., Yamauchi, S., Izumi, T. et al. (2002) Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary “brosis. Intern Med 41: 1118-1123.
90. Nagase, H. and Woessner Jr, J.F. (1999) Matrix metalloproteinases. J Biol Chem 274: 21491-21494.
91. Nakazato, H., Oku, H., Yamane, S., Tsuruta,Y. and Suzuki, R.A. (2002) novel anti-”brotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 446: 177-185.
92. Nash, J.R.G., McLaughlin, P.J., Butcher, D. and Corrin, B. (1993) Expression of tumour necrosis factor-α in cryptogenic “brosing alveolitis. Histopathology 22: 343-347.
93. Nicholson, A.G., Fulford, L.G., Colby, T.V. et al. (2002) The relationship between individual histologic features and disease progression in idiopathic pulmonary “brosis. Am J Respir Crit Care Med 166: 173-117.
94. Nicod, L.P. (1999) Pirfenidone in IPF. Lancet 354: 268-269.
95. Ogushi, F., Tani, K., Endo, T., Tada, H., Kawano, T., Asano, T. et al. (2001) Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary “brosis. J Med Invest. 48: 181-189.
96. Oshikawa, K. and Sugiyama,Y. (2000) Serum anti-p53 autoantibodies from patients with idiopathic pulmonary “brosis associated with lung cancer. Respir Med 94: 1085-1091.
97. Park, S.H., Saleh, D., Giaid, A. and Michel, R.P. (1997) Increased endothelin-1 in bleomycin-induced pulmonary “brosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156: 600-608.
98. Patel,Y.C. (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-198.
99. Phillips, R.J., Burdick, M.D., Hong, K., Lutz, M.A., Murray, L.A., Xue,Y.Y. et al. (2004) Circulating “brocytes traf”c to the lungs in response to CXCL12 and mediate “brosis. J Clin Invest 114: 438-446.
100. Pinney, C.T. and Harris, H.W. (1956) Hamman-Rich syndrome; report of a case diagnosed antemortem by lung biopsy and successfully treated with long-term cortisone therapy. Am J Med 20: 308-313.
101. Prior, C. and Haslam, P.L. (1992) In vivo levels and in vitro production of interferon-gamma in “brosing interstitial lung diseases. Clin Exp Immunol 88: 280-287.
102. Raghu, G., Depaso, W.J., Cain, K., Hammar, S.P., Wetzel, C.E., Dreis, D.F. et al. (1991) Azathioprine combined with prednisone in the treatment of idiopathic pulmonary “brosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144: 291-296.
103. Raghu, G., Johnson, W.C., Lockarht, D. and Mageto, Y. (1999) Treatment of Idiopathic Pulmonary Fibrosis with a New Anti”brotic Agent, Pirfenidone Am J Respir Crit Care Med 159: 1061-1069.
104. Raghu, G., Noble, P.W., Brown, K.K. and Colby, T.V. (2000) Interferon gamma-1b in idiopathic pulmonary “brosis: Reanalysis of a published study. American Thoracic Society Continuing Education Monograph Series 44-51.
105. Raghu, G., Brown, K.K., Bradford, W.Z., Starko, K., Noble, P.W., Schwartz, D.A. et al. (2004) Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary “brosis. N Engl J Med 350: 125-133.
106. Raghu, G., Fatenejad, S., McDermott, L. and the IPF Study Group. (2006) Ef”cacy and safety of etanercept in patients with idiopathic pulmonary “brosis (IPF). Eur Respir J 28: Suppl. 50, 767s.
107. Ramos, C., Montaño, M., García-Alvarez, J., Ruiz, V., Uhal, B.D., Selman, M. et al. (2001) Fibroblasts from idiopathic pulmonary “brosis and normal lungs differ in growth rate, apoptosis, and TIMPs expression. Am J Respir Cell Mol Biol 24: 591-598.
108. Rennard, S.I., Hunningake, G.W., Bitterman, P.B. and Crystal, R.G. (1981) Production of “bronectin by human alveolar macrophage: mechanism for the recruitment of “broblasts to sites of injury in interstitial lung diseases. Proc Natl Acad Sci USA 78: 7147-7151.
109. Richeldi, L., Davies, H.R., Ferrara, G. and Franco, F. (2003) Corticosteroids for idiopathic pulmonary “brosis. The Cochrane Library 3: CD002880.
110. Saleh, D., Furukawa, K., Tsao, M.S., Maghazachi, A., Corrin, B., Yanagisawa, M. et al. (1997) Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary “brosis: possible involvement of proin”ammatory cytokines. Am J Respir Cell Mol Biol 16: 187-193.
111. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A. and Kaplan, G. (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703.
112. Selman, M. (2003) A dark side of interferon-gamma in the treatment of idiopathic pulmonary “brosis? Am J Respir Crit Care Med 167: 945-947.
113. Selman, M., Carrillo, G., Salas, J., Padilla, R.P., Pérez-Chavira, R., Sansores, R. et al. (1998) Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary “brosis: a controlled clinical trial. Chest 114: 507-512.
114. Selman, M., Ruiz, V., Cabrera, S., Segura, L., Ramirez, R., Barrios, R. et al. (2000) TIMP-1-2,-3, and -4 in idiopathic pulmonary “brosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 279: L562-574.
115. Selman, M., King, T.E. and Pardo, A. (2001) Idiopathic pulmonary “brosis: prevailing and evolving hypothesis about its pathogenesis and implications for therapy. Ann Intern Med 134: 136-151.
116. Selman, M. and Pardo, A. (2002) Idiopathic pulmonary “brosis: an epithelial/”broblastic cross-talk disorder. Respir Res 3: 3
117. Sheppard, D. (2001) Pulmonary “brosis: a cellular overreaction or a failure of communication? J Clin Invest 107: 1501-1502.
118. Shi-Wen, X., Denton, C.P., Dashwood, M.R., Holmes, A.M., Bou-Gharios, G., Pearson, J.D. et al. (2001) Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116: 417-425.
119. Strausz, J., Muller-Quernheim, J., Steppling, H. and Ferlinz, R. (1990) Oxygen radical production by alveolar in”ammatory cells in idiopathic pulmonary “brosis. Am Rev Respir Dis 141: 124-128.
120. Strieter, R.M. (2005) Pathogenesis and Natural History of Usual Interstitial Pneumonia. The Whole Story or the Last Chapter of a Long Novel. Chest 128: 526S-532S.
121. Svegliati Baroni, S., Santillo, M., Bevilacqua, F., Luchetti, M., Spadoni, T., Mancini, M. et al. (2006) Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis N Engl J Med 354: 2667-2676.
122. Tabata, C., Tabata, R., Kadokawa,Y., Hisamori, S., Takahashi, M., Mishima, M., Nakano, T. et al. (2007) Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice. J Immunol 179: 708-714.
123. Takahashi, T., Wada, I., Ohtsuka,Y., Munakata, M., Homma,Y., Kuroki,Y. et al. (2007) Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary “brosis. Respirology. 12: 642-653.
124. Tavares, J.L., Wangoo, A., Dilworth, P., Marshall, B., Kotecha, S., Shaw, R.J. et al. (1997) Thalidomide reduces tumor necrosis factor-α production by human alveolar macrophages. Respir Med 91: 31-39.
125. Tomioka, H., Kuwata,Y., Imanaka, K., Hashimoto, K., Ohnishi, H., Tada, K. et al. (2005) A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary “brosis Respirology 10: 449-455.
126. Turner-Warwick, M., Burrows, B. and Johnson, A. (1980) Cryptogenic “brosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 35: 593-599.
127. Uhal, B.D., Joshi, I., Hughes, W.F., Ramos, C., Pardo, A., Selman, M. et al. (1998) Alveolar epithelial cell death adjacent to underlying myo”broblasts in advanced “brotic human lung. Am J Physiol 275: L1192-L1199.
128. Venuta, F., Rendina, E.A., Ciriaco, P., De Giacomo, T., Pompeo, E., Bachetoni, A. et al. (1993) Ef”cacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary “brosis before lung transplantation. J Heart Lung Transplant 12(6Pt1): 909-914.
129. Waghray, M., Cui, Z., Horowitz, J.C., Subramanian, I.M., Martinez, F.J., Toews, G.B. et al. (2005) Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myo”broblasts. FASEB J 19: 854-856.
130. Wallace, W.A. and Howie, S.E. (1999) Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 187(4): 475-480.
131. Wallace, W.A., Ramage, E.A., Lamb, D. and Howie, S.E. (1995) A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic “brosing alveolitis (CFA). Clin Exp Immunol 101(3): 436-441.
132. Walter, N., Collard, H.R. and King Jr., T. E. (2006) Current perspectives on the treatment of idiopathic pulmonary “brosis. Proc Am Thorac Soc 3: 330-338.
133. Yang,Y., Fujita, J., Bandoh, S., Ohtsuki, Y., Yamadori, I., Yoshinouchi, T. et al. (2002) Detection of antivimentin antibody in sera of patients with idiopathic pulmonary “brosis and non-speci”c interstitial pneumonia. Clin Exp Immunol 128: 169-174.
134. Ye, Q., Chen, B., Tong, Z., Nakamura, S., Sarria, R., Costabel, U. and Guzman, J. (2006) Thalidomide reduces IL-18, IL-8 and TNF-a release from alveolar macrophages in interstitial lung disease. Eur Respir J 28: 824-831.
135. Zhang, H.Y. and Phan, S.H. (1999) Inhibition of myo”broblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 21: 658-665.
136. Ziesche, R., Kink, E., Herold, C., Podolsky, A. and Block, L.H. (1996) Therapy of chronic interstitial lung disease with a combination of interferon-gamma and low-dose prednisolone. Chest 110: Suppl: 25S.
137. Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V. and Block, L.H. (1999) A pre liminary study of long-term treatment with interferon gamma 1b and low-dose prednisolone in patients with idiopathic pulmonary “brosis. The New England Journal of Medicine 341: 1264-1269.
138. Zisman, D.A., Lynch, J.P. 3rd, Toews, G.B., Kazerooni, E.A., Flint, A., Martinez, F.J. et al. (2000) Cyclophosphamide in the treatment of idiopathic pulmonary “brosis: a prospective study in patients who failed to respond to corticosteroids. Chest 117: 1619-1626.